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ABSTRACT
Introduction: This retrospective cohort study
investigated the relation between different
measures of glycemic exposure and micro- and
macrovascular complications among patients
with type 2 diabetes.
Methods: The analysis included patients
receiving oral antihyperglycemic agents
between 1 January 2006 and 31 December 2014
from the General Practitioner Database from
the PHARMO Database Network. All recorded
HbA1c levels during follow-up were used to
express glycemic exposure in four ways: index
HbA1c, time-dependent HbA1c, exponential
moving average (EMA) and glycemic burden.
Association between glycemic exposure and
micro-/macrovascular complications was ana-
lyzed by estimating hazard ratios and 95%
confidence intervals using an adjusted
(time-dependent) Cox proportional hazards
model.
Results: The analysis included 32,725 patients
(median age, 65 years; 47% female). Median
follow-up was 5.4 years; median number of
HbA1c measurements per patient was 18.0.
From all measures, HbA1c at index showed the
weakest relation between all micro-/macrovas-
cular complications, with coronary artery dis-
ease (CAD) having the highest HR (95% CI):
1.18 (1.04–1.34) for HbA1c C64 mmol/mol
(8%). The time-dependent HbA1c model
showed a significant association only for
microvascular complications, with retinopathy
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having the highest HR (95% CI): 1.55
(1.40–1.73) for HbA1c C64 mmol/mol (8%).
EMA-defined exposure showed similar findings,
although the effect of retinopathy was more
pronounced [HR (95% CI): 1.81 (1.63–2.02) for
HbA1c C64 mmol/mol (8%)] and was also pre-
dictive for CAD [HR (95% CI): 1.29 (1.10–1.50)
for HbA1c C64 mmol/mol (8%)]. A statistically
significant relation with glycemic burden was
found for all selected micro-/macrovascular
complications, with retinopathy having the
highest HR (95%): 2.60 (2.19–3.07) for glycemic
burden years[3.
Conclusion: This study shows that greater and
more prolonged exposure to hyperglycemia
increases the risk of micro- and macrovascular
complications.
Funding: Janssen Pharmaceutica NV.
Keywords: Glycemic burden; Macrovascular;
Microvascular; Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a complex
disease with many associated long-term com-
plications and a major impact on the daily lives
of patients. High glycemia shows a positive
correlation with both micro- and macrovascular
complications [1–3]. Therefore, to prevent or
slow these complications, good glycemic con-
trol is thought to be important [4]. In general
practice, glycosylated hemoglobin (HbA1c) is
often used as a measure of glycemic control.
The advantage of using HbA1c as opposed to
blood glucose level is that it measures the
average plasma glucose level over a period of
2–3 months [5]. The HbA1c target is generally
53 mmol/mol (7%) [6]; nevertheless, T2DM
patients often do not reach the recommended
glycemic target and stay uncontrolled for long
periods of time [7].
When assessing the risk associated with high
glycemia, HbA1c measurements are often eval-
uated at a single point in time, which can lead
to an underestimation of the role of HbA1c as a
risk factor [8, 9], as it does not take the level of
glycemic control over time into account. An
updated mean (UM) HbA1c is sometimes used
instead of the single measure as a more appro-
priate approximation of glycemic exposure as it
is calculated as the average of all previous
measurements and is recalculated if new mea-
surements are added [1]. Using an UM has been
shown to have greater predictive power [1, 10];
however, while an UM does reflect the level of
hyperglycemia over time, irregular intervals
between measurements may have a significant
impact. Infrequent measurements during high
glycemic levels, mixed with frequent measure-
ments during low glycemic levels, may lead to
underestimation of the glycemic exposure over
time and vice versa. The UM does not distin-
guish between recent and historic hyper-
glycemic periods. To allow recent glycemic
levels to have more impact, more weight can be
assigned to recent measurements in the UM
[i.e., exponential moving average (EMA)].
However, this might also lead to diminished
impact of historic periods of hyperglycemia. By
calculating an area under the curve (AUC) of
glycemic exposure, the effect of all measure-
ments is taken into account, independent of
whether the measurement is recent or in the
past, but taking into account the duration of
hyperglycemic periods as well as the extent of
the hyperglycemia. This is referred to as gly-
cemic memory [11–13].
The objective of this study is to investigate
the relation between glycemic exposure and
micro- and macrovascular complications
among patients with T2DM using real-world
data. To further investigate the effect of changes
in HbA1c on long-term outcomes, different
measures of glycemic exposure are used,
including single point measurements, EMA and
AUC.
METHODS
Setting
For this observational cohort study, data were
obtained from the PHARMO Database Network.
This population-based network of Dutch elec-
tronic healthcare databases combines rich,
patient-centric data from different primary and
secondary healthcare settings. Data from the
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General Practitioner (GP) Database were used,
which cover approximately 2.5 million patients
from 2005 to 2014. The GP Database comprises
data from electronic patient records registered
by GPs. The health records include information
on diagnoses and symptoms, laboratory test
results, referrals to specialists and healthcare
product/drug prescriptions. The prescription
records include information on the type of
product, prescription date, strength, dosage
regimen, quantity and route of administration.
Drug prescriptions are coded according to the
WHO Anatomical Therapeutic Chemical (ATC)
Classification System. Diagnoses and symptoms
are coded according to the International Clas-
sification of Primary Care (ICPC), which can be
mapped to ICD codes, but can also be entered as
free text. The study period was defined as 1
January 2006–31 December 2014.
Patient Involvement
As this was an observational study using retro-
spective data, patients were not involved in the
study design or conduct.
Study Population
To investigate the relation between multiple
measures of glycemic exposure and macro- and
microvascular complications, it was important
to have regularly recorded HbA1c measure-
ments. Diabetes care in The Netherlands is
mainly managed in the primary care setting and
guided by the Dutch GP guideline for T2DM
[14]. It is well organized, including regular
checkups. For our study, only general practices
adhering to these regular checkups were selec-
ted, which was defined as having at least 50% of
its T2DM patients with at least three HbA1c
measurements per year. This selection was done
at the practice level instead of patient level to
avoid biased selection as well-managed patients
with T2DM may be monitored less frequently.
Within the selected practices, T2DM patients
were identified as having either a diagnosis code
(ICPC code T90.02) or at least two consecutive
prescriptions of oral antihyperglycemic agents
(AHA; ATC code A10B) within a 6-month period
at any time in the available medication records.
The index date was defined as the first oral AHA
prescription after at least 1 year of enrollment.
Patients without any oral AHA prescriptions
during the study period were excluded as well as
patients with diagnoses for T1DM, gestational
diabetes or polycystic ovary syndrome (PCOS).
Only patients between 40 and 84 years of age at
the index date were included. The most recent
HbA1c measurement within 1 year prior to or at
the index date was defined as the index HbA1c
measurement. If an index HbA1c measurement
was not available, the patient was excluded.
Further exclusions were based on the event of
interest. Patients with a prior event were
excluded for the analysis of that specific event
but were possibly included in other analyses.
Finally, patients were required to have at least
one HbA1c measurement during follow-up.
Again, this could differ per event of interest,
since the end of follow-up was determined as
either the first occurrence of an event, death,
loss to follow-up in the PHARMO Database
Network or end of the study period, whichever
occurred first.
The following characteristics were deter-
mined: age at index date, gender, HbA1c at
index date, the proportion of prior complica-
tions at index date, newly treated, follow-up,
number of HbA1c measurements during fol-
low-up and BMI at the index date. Newly trea-
ted patients were defined as those without any
AHA prescription in the year prior to the index
date.
Outcomes
Diabetic foot, retinopathy and renal complica-
tions were the microvascular events of interest,
and coronary artery disease (CAD) and cere-
brovascular disease were the macrovascular
events of interest. All complications were based
on GP-recorded information.
Microvascular Complications
Diabetic foot was identified based on recorded
codings and text searches for the diagnoses of
necrosis, ulcer, diabetic foot, infection, wound,
erysipelas, gangrene, Charcot foot, loss of
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protective sensation, peripheral artery disease,
peripheral arterial occlusive disease, claudica-
tion, neuropathy and amyotrophy [15, 16]. The
positive clinical assessments of necrosis and
ulcers were also included.
Retinopathy was identified based on ICPC
code F83 (retinopathy), positive outcomes of
retinopathy assessments and text searches for
the diagnoses of retinopathy, maculopathy or
diabetic macular edema.
Renal complications were identified based
on multiple assessments of the estimated
glomerular filtration rate \60 ml/min/1.73 m2
[modification of the Diet in Renal Disease
(MDRD) formula] or proteinuria (albumin
[30 mg/l), at least 90 days and at most 365 days
apart, or on searches for the diagnoses of
nephropathy, nephrotic syndrome, glomerular
hematuria, glomerulonephritis, nephrosis, kid-
ney failure, dialysis, transplants, proteinuria
and albuminuria.
Macrovascular Complications
The identification of CAD was based on ICPC
codes K53 (coronary artery angioplasty), K74
(angina pectoris), K75 (myocardial infarction)
and K76 (ischemic heart disease) and searches
for the diagnoses of angina pectoris, acute
coronary syndrome (ACS) and myocardial
infarction. Cerebrovascular disease-related
events were identified based on ICPC codes K89
[transient ischemic attack (TIA)] and K90
[stroke/cerebrovascular accident (CVA)] as well
as searches for the diagnoses of stroke, cerebral
infarction, CVA and TIA.
Glycemic Exposure
Four different definitions of glycemic exposure
were studied. A first definition of exposure was
based on the HbA1c at index [3, 17, 18], defined
as the last HbA1c measurement in the year prior
to the index date. A second definition of gly-
cemic exposure was based on all observed
HbA1c measures during post-index follow-up;
HbA1c was included as a time-dependent
covariate. The third approach was similar to the
previous one, but instead of including observed
HbA1c values, the exponential moving average
(EMA) of HbA1c was included as a
time-dependent covariate. The exponential
moving average (EMA) is a variant of the
updated mean (UM) [1, 17]. In this measure, the
current HbA1c measurement amounts to 20%
of the calculated value, and the previously cal-
culated EMA amounts to 80%. The EMA was
chosen to ensure that, independent of the total
number of measurements, the last measure-
ment is given a fixed weight of 0.2. In a fourth
approach, the glycemic burden was calculated,
defined as the AUC given a threshold of
53 mmol/mol (7%) [13]. Between two HbA1c
measurements a linear interpolation was used,
and the glycemic burden over a time period was
calculated when either a new HbA1c measure-
ment occurred or the age of a patient changed.
At the start of a given time period, the cumu-
lative glycemic burden was defined as the sum
of all the calculated AUCs up until then. Fur-
thermore, the cumulative glycemic burden is
divided by 365 to express the value in years. The
calculation of the glycemic burden years (GBY)
is presented graphically in Fig. 1. The GBY was
included as a time-dependent variable in the
Cox-model.
Partial GBYs (AUC1, AUC2, etc.) were calcu-
lated per interval between cutoff points as the
difference in HbA1c above the threshold of
53 mmol/mol (7%) multiplied by the number of
years between those points. Cutoff points were
HbA1c measurements, changes in age or inter-
polation lines crossing the threshold. Cumula-
tive GBY was updated at each of the cutoff
points by summing all prior GBYs.
Statistical Analysis
Population characteristics were reported as
absolute and relative frequencies (n, %) for cat-
egorical variables and as median and
interquartile range (IQR) for continuous vari-
ables, if applicable. Incidence rates (IRs) were
calculated per type of event by dividing the
number of patients with an event by the total
number of patient-years at risk (summed dura-
tions of total treatment period, censored at the
time of the event under investigation).
A Cox proportional hazards regression anal-
ysis was performed for each of the micro- and
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macrovascular complications with each of the
four glycemic exposure measures. The PROC
PHREG procedure from SAS 9.4 was used.
For the model, using HbA1c at index, the
Cox proportional hazards regression model was
adjusted for age, gender and the year of index.
For illustration, the HbA1c value at index was
categorized as \53 mmol/mol (7%), 53 to
\64 mmol/mol (7% to \8%) and
C64 mmol/mol (8%). For the other models,
repeated measurements of HbA1c were inclu-
ded, and a time-dependent Cox proportional
hazards regression analysis was performed. Age
and the measure of exposure (HbA1c, EMA or
GBY) were used as time-dependent variables,
and the model was corrected for age, gender,
the year of index and time (in years) since the
first measurement above 53 mmol/mol (7%)
and the time (in years) since the last measure-
ment below 53 mmol/mol (7%). The time-
dependent HbA1c and the EMA were catego-
rized as follows: \53 mmol/mol (7%), 53 to
\64 mmol/mol (7% to \8%) and
C64 mmol/mol (8%). The categorization of
glycemic burden was based on its distribution: 0
(reference),[0 to B1,[1 to B3 and[3 GBYs.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. No ethics committee
approval or informed consent was required for
this anonymized database study.
RESULTS
Patients
The flow chart describing the process of patient
selection is shown in Fig. 2. After applying all
inclusion and exclusion criteria, approximately
30,000 patients were included per outcome. The
characteristics of the total population, without
exclusions of patients with prior events, are
shown in Table 1. Median (IQR) age was 65
(57–73) years, and approximately half of the
patients were female (47%). At index date, 50%
of the patients were on target [HbA1c\53
mmol/mol (7%)], and only 18% of the patients
had an HbA1c at index C 64 mmol/mol (8%).
Glycemic Exposure
In total, 20 analyses were performed, and the
results are presented in Fig. 3 and summarized
in Supplemental Table S1. The results of the
different events are plotted separately, with the
hazard ratios (HRs) on the vertical axis. Within
each plot, the four different measures of gly-
cemic exposure are displayed with the HR per
categorized variable.
The results for the first model, using only the
HbA1c at index, suggested an increased risk for
higher HbA1c values for the microvascular
Fig. 1 Calculation of GBYs. AUC area under the curve, GBY glycemic burden year
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complications as well as CAD. However, the
results were only significant for the highest
category [HbA1c C64 mmol/mol (8%)] for renal
complications [HR (95% CI) of 1.10 (1.02–1.18)]
and CAD [HR (95% CI) of 1.18 (1.04–1.34)]
compared to the reference category [HbA1c
\53 mmol/mol (7%)].
The results for the time-dependent HbA1c
model showed an increased risk for both
diabetic foot and retinopathy. For diabetic foot,
the HRs (95% CI) for the middle and highest
HbA1c categories were 1.09 (1.00–1.19) and
1.36 (1.21–1.52), respectively. For retinopathy,
this was 1.19 (1.10–1.30) and 1.55 (1.40–1.73),
respectively. For renal complications, only the
highest HbA1c category showed a significant
association [HR (95% CI): 1.20 (1.10–1.31)]. The
associations between time-dependent HbA1c
Fig. 2 Flow chart of patient selection. GP general prac-
titioner, PCOS polycystic ovary syndrome, T1DM type 1
diabetes mellitus, T2DM type 2 diabetes mellitus. *The
ﬁrst antihyperglycemic prescription after at least 1 year of
enrollment in the database. Follow-up differed per event
of interest as patients were followed from the index date to
end of follow-up [i.e., ﬁrst occurrence of the event of
interest, death, loss to follow-up in the PHARMO
Database Network or end of the study period (31
December 2014), whichever occurred ﬁrst]
1102 Diabetes Ther (2017) 8:1097–1109
and macrovascular complications were not
significant.
The results for the third model, using the
EMA, were very similar to the results of the
previous model with a few notable exceptions.
Specifically, the HRs for retinopathy were
markedly higher for both the middle and
highest HbA1c categories [i.e., HRs (95% CI) of
1.29 (1.18–1.41) and 1.81 (1.63–2.02), respec-
tively]. Also, the results for CAD were significant
for the highest category [HbA1c C64 mmol/mol
(8%); HR (95% CI) of 1.29 (1.10–1.50)].
The results for the glycemic burden model
showed significantly increased risks associated
with higher GBY levels for the microvascular
complications. For diabetic foot, the HRs were
1.30, 1.46 and 2.15 for[0 to B1,[1 to B3 and
[3 GBYs, respectively, compared to the refer-
ence category of no glycemic burden. For
retinopathy, the HRs ranged from 1.41 to 2.60,
and for renal complications, the HRs ranged
from 1.20 to 1.61. The macrovascular compli-
cations showed similar results. However, for
coronary artery disease GBY[1 to B3, the HR
was not significantly higher. Cerebrovascular
disease on the other hand did show a dose
response relation where the HRs ranged from
1.20 to 1.52.
Additional results of the models, including
the covariates, are included in Online Resource
1 (Supplemental Table S2).
Table 1 Characteristics of patients with T2DM
Total
N5 32,725
Age at index date, years
Median (IQR) 65 (57–73)
Gender, n (%)
Male 17,270 (53)
Female 15,455 (47)
HbA1c at index date, n (%)
\53 mmol/mol (7%) 16,325 (50)
53 mmol/mol (7%) to\58 mmol/mol
(7.5%)
6582 (20)
58 mmol/mol (7.5%) to\64 mmol/mol
(8%)
3771 (12)
C64 mmol/mol (8%) 6047 (18)
Median (IQR) 53.0
(46.4–59.6)
Prior complications at index date, n (%)
Microvascular
Diabetic foot 1531 (5)
Retinopathy 570 (2)
Renal complications 3679 (11)
Macrovascular
Coronary artery disease 1526 (5)
Cerebrovascular disease 848 (22)
Newly treated
Yes 13,656 (42)
No 19,069 (58)
Follow-up, years
Median (IQR) 5.4 (2.5–7.8)
Number of HbA1c measurements
Median (IQR) 18.0
(8.0–29.0)
BMI, kg/m2a
Table 1 continued
Total
N5 32,725
Median (IQR) 29.7
(26.8–33.3)
BMI body mass index, IQR interquartile range, T2DM
type 2 diabetes mellitus
a BMI was determined in the year prior to the index date
and was available for 65% of the patients. The incidence
rates of the micro- and macrovascular events are presented
in Table 2. The incidence rate of microvascular events
ranges from 2.5 new retinopathy cases per 100 patient--
years (PYs) to 6.0 new renal complication cases per 100
PYs, and the incidence rates of macrovascular events were
between 1 and 1.4 events per 100 PYs
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DISCUSSION
Main Findings
All micro- and macrovascular complications
were weakly associated with exposure to high
HbA1c [HbA1c C64 mmol/mol (8%)] at index to
some extent, but this was only significant for
renal complications [HR (95% CI) of 1.10
(1.02–1.18)] and CAD [HR (95% CI) of 1.18
(1.04–1.34)]. When modeling glycemic expo-
sure as the time-dependent observed HbA1c, a
significantly increased risk for all microvascular
Fig. 3 Association between different measures for glycemic exposure and micro- and macrovascular complications. CI
conﬁdence interval, EMA exponential moving average, HR hazard ratio
Table 2 Incidence rates (95% CI) of micro- and macrovascular complications
Nat risk PYat risk Nevent IR/100 PY (95% CI)
Microvascular complications
Diabetic foot 31,194 147,440 3904 2.65 (2.57–2.73)
Retinopathy 32,155 150,465 3764 2.50 (2.42–2.58)
Renal complications 29,046 124,708 7507 6.02 (5.88–6.16)
Macrovascular complications
Coronary artery disease 31,199 151,921 2129 1.40 (1.34–1.46)
Cerebrovascular disease 31,877 156,966 1664 1.06 (1.01–1.11)
CI conﬁdence interval, IR incidence rate, PY patient-year
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complications was observed for HbA1c
C64 mmol/mol (8%). For the macrovascular
events, this model was inconclusive, and the
results were not significant. These results are
largely in line with other findings. For renal
complications, Gerstein et al. [17] found an
association between an increase in HbA1c at
index and nephropathy, and Klein [3] found an
association between an increase in HbA1c at
index and both gross proteinuria and renal
failure. For diabetic foot, an increased risk was
expected for the model using the HbA1c value
at index in concordance with earlier findings
[3, 18]; however, these studies found associa-
tions with either amputation [3] or sensory
neuropathy [18], while we defined a composite
endpoint covering a broad spectrum of periph-
eral arterial problems. However, our findings do
suggest that the most recent HbA1c measure-
ment (i.e., time-dependent HbA1c) is a better
predictor for diabetic foot than the HbA1c at
index. For CAD, the results regarding HbA1c at
index are in concordance with the literature
[10] where an HR (95% CI) of 1.05 (1.00–1.10)
was reported for a 1% increase in HbA1c also
using the HbA1c at index. On the other hand,
no significant effect was found for the
time-dependent HbA1c, suggesting that the
HbA1c at index is a better predictor for CAD
than the most recent HbA1c measurement. The
results for cerebrovascular disease were incon-
clusive, which is in line with other findings [10]
where an HR (95% CI) of 0.96 (0.88–1.06) for a
1% increase of HbA1c at index was reported.
The EMA-based results for the microvascular
events showed similar results as the time-de-
pendent HbA1c. Retinopathy specifically
showed a clear dose response for EMA, and
associations were stronger than in the time-de-
pendent HbA1c model. For the macrovascular
event of coronary artery disease, a significantly
increased risk was observed in the highest risk
category [EMA C64 mmol/mol (8%)]. Again, the
results for cerebrovascular disease were incon-
clusive. An association between the increase in
updated mean HbA1c and the risk has been
reported for diabetic foot [1], retinopathy
[8, 19], renal failure [17], CAD [1, 2] and cere-
brovascular disease [1]. With the exception of
cerebrovascular disease, our results reflected
previously reported findings. Absence of an
association between EMA and the risk of cere-
brovascular disease may be explained by the fact
that we defined cerebrovascular disease as a
composite endpoint including stroke, TIA, CVA
and cerebral infarction, while Stratton et al. [1]
reported an HR (95% CI) of 1.14 (1.01–1.27) for
a 1% increase in updated mean HbA1c for stroke
only. For the microvascular events, the analyses
using glycemic burden showed the clearest dose
response. Overall, the HRs were higher, but the
categories used were different from the previous
models and not directly comparable as the GBY
categories of this cumulative outcome were
based on the distribution of the number of
patients rather than clinically recognizable
cutoff points for HbA1c. Again, the effects for
retinopathy were stronger than for the other
microvascular events: the HRs ranged from 1.41
to 2.60 against 1.30–2.15 for diabetic foot and
1.20–1.61 for renal failure. Maple-Brown et al.
[13] used the AUC as a measure for chronic
glycemic exposure and found that it was a good
predictor for microvascular complications. For
the macrovascular events, CAD (GBY[0 to B1
and GBY[3) showed a significant association.
Cerebrovascular disease showed a significant,
albeit small, dose response with HRs ranging
from 1.20 to 1.51.
Strengths and Limitations
A strength of the study is the use of a large
population in a real-world setting with long
follow-up. Data from GPs in The Netherlands
are especially suited, since diabetes care in The
Netherlands is highly organized, and the
majority (90%–95%) of T2DM patients are
treated within the primary care setting. This
means that we were able to validate our models
in actual clinical practice.
A limitation is that the duration of diabetes
was not included in the model because it is not
always explicitly recorded as a clinical parame-
ter. We also did not differentiate between
patients who were and were not newly treated.
Both have resulted in underestimation of the
glycemic burden and are likely to have resulted
in an underestimation of the associations.
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However, available data reflect the situation in
the daily practice of any physician, who will not
always know the glycemic history of a patient
and will act on the data available at the time of
a visit. Furthermore, we performed post hoc
analyses, correcting for newly initiated or
prevalent use of AHA at the time of the index
date, to test whether underestimation of the
glycemic burden of patients that were already
treated at the start of their recorded history
might have caused underestimation of the
associations with complications. The results
were very similar to the main analysis and
therefore could not support this assumption.
This means that even with incomplete records,
all available history of a patient may provide
valuable information to a physician regarding
the build-up of glycemic memory. One of the
limitations of real-world evidence in general is
that information is not collected or recorded for
the purpose of doing research. Changes in dis-
ease management have had a major impact on
the way complications were recorded during the
study period, leading to more detailed outcome
recording over time. To allow analysis of more
or less similar outcomes over time, composite
endpoints had to be used. For example, in the
case of diabetic foot, this resulted in a mix of
micro- and macrovascular causes. This loss of
specificity may have weakened the association
of specific contributing factors within the
composite. Future studies may be able to clarify
specific associations by using more specific
outcome definitions. In 2006, an integrated
diabetes care program was introduced, with
structured management and regular checkups
of the patient by an interdisciplinary team of
GPs, diabetes nurses, podiatrists and ophthal-
mologists. Check-ups include assessment of
HbA1c, renal function, retinopathy, (early)
signs of diabetic foot and history taking with
regard to macrovascular complications. The
gradual rollout of this integrated care was
boosted by financial incentives linked to
developing performance indicators offered by
healthcare insurance companies to GPs from
mid-2007 onward. This is reflected in the data
by a steady increase in the recorded number of
complications, which was about fivefold over
the whole study period. As 40% of our
population had an index date before 2008, this
means that a significant number of patients
may have been misclassified as having no
complications at the index date and that some
complications now registered as newly devel-
oped may have been pre-existing. Incidence
rates may therefore have been overestimated. As
this possible misclassification was most likely
irrespective of HbA1c levels, we do not believe
that this non-differential misclassification has
influenced our results to a large extent. Finally,
we have not taken treatment into account,
while the type of treatment may influence
outcomes through other mechanisms than
glucose lowering. For future research, it would
be very valuable to take the type of treatment
and other potential risk factors into account.
Implications for Clinical Practice
The first two models used a single point mea-
surement as a predictor for outcomes, where
this single point can either be static (i.e., HbA1c
at index) or time updating (i.e., time-dependent
HbA1c). The static model is highly practical for
database studies, while the time-updating
model better reflects the interpretation a
physician might apply in daily practice (i.e., use
of the last known value for risk assessment).
However, it should be noted that the results of
the current study show that neither of these
models is necessarily a good representation of
the risk to which an individual is exposed. The
EMA, on the other hand, shows a stronger
relation with diabetic foot, retinopathy and
CAD, if not with the other outcomes, which
does suggest that glycemic memory plays a role
in these outcomes. This is further corroborated
by the results of the glycemic burden model
where these associations are more pronounced
and even become apparent for the macrovas-
cular complications. Given that the glycemic
burden model gives a better discrimination
between patients that do or do not develop
complications, it is a very promising method for
further research into the long term effects of
hyperglycemia. This could contribute valuable
evidence to influence clinical decision making.
All in all, the results from this study show that
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longer exposure to HbA1c levels above target is
associated with increased risk of both micro-
and macrovascular complications. Furthermore,
the results suggest that glycemic memory plays
a role in the development of diabetic compli-
cations and that treatment inertia increases the
risk of these outcomes in broad populations of
patients with T2DM who are not on target [20].
From the individual patient perspective, how-
ever, it is important to note that intensive glu-
cose-lowering treatment aiming at a low target
HbA1c may lead to increased risk of hypo-
glycemia or adverse drug reactions and there-
fore is not recommended for patients of older
age or with short life expectancy, important
comorbidities or poor self-care capabilities [6].
This is why the most recent revision of the
diabetes guidelines for T2DM [21] has included
higher targets for patients over 70 years of age
who cannot be managed with metformin alone.
Our finding that glycemic memory plays an
important role in the development of compli-
cations emphasizes the importance of physi-
cians keeping in mind that lower targets are
probably more beneficial for a patient, provided
that they are attainable without the trade-off of
increased immediate risk. This underlines the
need for frequent and active monitoring of the
diabetes patient.
CONCLUSION
This study shows that greater and more pro-
longed exposure to hyperglycemia is associated
with increased risk of both micro- and
macrovascular complications. The possibility of
damage caused by clinical inertia is something
that needs to be addressed in clinical practice.
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